X

Xiamen Amoytop Biotech Co Ltd
SSE:688278

Watchlist Manager
Xiamen Amoytop Biotech Co Ltd
SSE:688278
Watchlist
Price: 71.69 CNY -3.54% Market Closed
Market Cap: 29.2B CNY
Have any thoughts about
Xiamen Amoytop Biotech Co Ltd?
Write Note

Xiamen Amoytop Biotech Co Ltd
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Xiamen Amoytop Biotech Co Ltd
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
X
Xiamen Amoytop Biotech Co Ltd
SSE:688278
Pre-Tax Income
ÂĄ640.7m
CAGR 3-Years
66%
CAGR 5-Years
114%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Pre-Tax Income
-ÂĄ6.2B
CAGR 3-Years
18%
CAGR 5-Years
-5%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Pre-Tax Income
ÂĄ1.4B
CAGR 3-Years
22%
CAGR 5-Years
37%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Pre-Tax Income
ÂĄ2.2B
CAGR 3-Years
9%
CAGR 5-Years
N/A
CAGR 10-Years
23%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Pre-Tax Income
ÂĄ7B
CAGR 3-Years
-6%
CAGR 5-Years
25%
CAGR 10-Years
47%
Imeik Technology Development Co Ltd
SZSE:300896
Pre-Tax Income
ÂĄ2.2B
CAGR 3-Years
62%
CAGR 5-Years
72%
CAGR 10-Years
N/A
No Stocks Found

Xiamen Amoytop Biotech Co Ltd
Glance View

Market Cap
29.2B CNY
Industry
Biotechnology

Xiamen Amoytop Biotech Co. Ltd. engages in the research and development of genetic engineering technology. The company is headquartered in Xiamen, Fujian and currently employs 1,261 full-time employees. The company went IPO on 2020-01-17. The firm's main research and development direction is immune-related cytokine drugs, focusing on systemic immune solutions based on cytokine drugs, and its products mainly include Peginterferon alfa-2b Injection, rhGM-CSF (Recombinant Human Granulocyte/Macrophage Colony-Stimulating Factor for Injection), rHuG-CSF (Recombinant Human Granulocyte-Colony Stimulating Factor for Injection) and Recombinant Human Interleukin-11 for Injection. The firm distributes its products within domestic market and to overseas markets.

Intrinsic Value
86.96 CNY
Undervaluation 18%
Intrinsic Value
Price
X

See Also

What is Xiamen Amoytop Biotech Co Ltd's Pre-Tax Income?
Pre-Tax Income
640.7m CNY

Based on the financial report for Dec 31, 2023, Xiamen Amoytop Biotech Co Ltd's Pre-Tax Income amounts to 640.7m CNY.

What is Xiamen Amoytop Biotech Co Ltd's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 5Y
114%

Over the last year, the Pre-Tax Income growth was 80%. The average annual Pre-Tax Income growth rates for Xiamen Amoytop Biotech Co Ltd have been 66% over the past three years , 114% over the past five years .

Back to Top